Medivir (MVIR) Status Update summary

Clinical trial results and efficacy

• Mature phase 1b/2a data show fostrox + Lenvima achieved a median time to progression of 10.9 months in advanced liver cancer, significantly longer than typical outcomes for second-line patients.

• Objective response rate reached 24%, with a median duration of response of 7.0 months.

• 19% of patients remained on treatment for over a year, and the longest patient continued for more than two years with sustained partial response.

• Patients benefited from the combination regardless of their response to previous therapies.

Safety and tolerability

• Safety profile supports long-term combination use, with only one patient discontinuing fostrox due to adverse events.

• No unexpected adverse events or fostrox-related serious adverse events were observed.

• Hematological adverse events were common but temporary, with cyclic recovery allowing continued treatment.

• No cases of febrile neutropenia or bleeding due to low platelet count occurred.

Next steps and strategic outlook

• Preparations are underway for a phase 2b randomized study comparing fostrox + Lenvima to Lenvima alone.

• The webcast presenting these results is scheduled for September 16, 2024.